S
Simnova
Biotech & Life Sciences · China · Founded 2019
Simnova Bio is a clinical stage biotechnology company focused on developing Cell Therapies to treat cancer MoreLess
Simnova Biotherapeutics is a clinical-stage biotechnology company dedicated to developing advanced cell therapies for cancer treatment. Founded in 2019 as the cell therapy discovery arm of Simcere Pharmaceuticals in Cambridge, MA, Simnova became an independent entity in 2021 with operations in both China and the United States. The company focuses on creating best-in-class cell therapies, aiming to revolutionize cancer treatment through innovative biotechnological solutions.
Simnova Biotherapeutics primarily serves patients battling various forms of cancer, offering them cutting-edge therapeutic options that leverage the latest advancements in cell therapy. The company operates in the highly competitive biotechnology market, where it distinguishes itself through its strong research and development capabilities and strategic partnerships.
The business model of Simnova Biotherapeutics revolves around the development, clinical testing, and eventual commercialization of its cell therapy products. Revenue is generated through a combination of research grants, partnerships with pharmaceutical companies, and future sales of approved therapies. By focusing on both the U.S. and Chinese markets, Simnova aims to maximize its reach and impact in the global fight against cancer.
Keywords: cell therapy, cancer treatment, biotechnology, clinical-stage, innovation, research and development, biopharmaceutical, oncology, global operations, advanced therapies.
Company overview
Simnova company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- China
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 20.0
Valuation & funding
Simnova funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Aug 2026 | $55M | $220M | Youshan Capital · Yuanhe Holdings · FT Capital · Qianji Capital | ↗ |
| SERIES A✓Equity / VC | Mar 2024 | $28M | $110M | Youshan Capital · Yuanhe Yuandian · Pudao Capital · Guochuang Qinzhi | ↗ |
Growth signals
Simnova website traffic
Latest recorded traffic for Simnova is 420 monthly website visits, up 23.5% over the last three months.
Comparisons
Simnova compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Simnova's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Simnova's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Simnova has talent and traffic
In the news
Latest news about Simnova
Recent press, funding announcements, and product moves mentioning Simnova — open to read from the original sources.
Market sentiment
What the market is saying about Simnova
An AI-synthesized read of the highest-engagement posts about Simnova on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Simnova’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.